WOBURN, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022 . Dr.
WOBURN, Mass. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021 . The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological
WOBURN, Mass. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care . Ms. Bell will be responsible for growing the Company's DPNCheck ® business with a primary focus on
WOBURN, Mass. , Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021 . The Company will host a conference call at 8:00 a.m., Eastern Time on October 21,
WOBURN, Mass. , Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults.
WOBURN, Mass. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. C2SHIP is a U.S. National Science Foundation (NSF) funded consortium of leading academic centers and
WOBURN, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research .
WOBURN, Mass. , July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021 . The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological
WOBURN, Mass. , July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell ® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.
WOBURN, Mass. , July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2021
